Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
EWEdwards Lifesciences Corporation logo

Edwards Lifesciences Corporation (EW)

New York Stock Exchange · Currency in USD
$89.07 ▼ -1.02 (-1.13%)
At close: Oct 23, 4:00 PM ET. Market closed.
$90.23 ▲ +1.16 (+1.30%)
After hours: Oct 23, 7:37 PM ET

Summary

Previous Close
$90.09
Open
$90.11
Day's Range
$89.00 – $91.05
52 Week Range
$74.66 – $96.29
Volume
3,101,386
Avg. Volume
3,960,552
Market Cap
$51.34B
Beta (5Y Monthly)
0.86
PE Ratio (TTM)
51.19
EPS (TTM)
$1.74
Earnings Date
Nov 4, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$104.63

Profile: Edwards Lifesciences Corporation

Sector
Healthcare
Industry
Medical - Devices
Full-time employees
16,000
CEO
Bernard J. Zovighian

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems.

Earnings

Next report: Wed, Nov 4, 2026
EPS estimate $0.74 · Revenue est. $1.68B
DateEst.Actual
Jul 23, 2026$0.74$0.78Beat
Apr 23, 2026$0.73$0.78Beat
Feb 10, 2026$0.62$0.58Miss
Oct 30, 2025$0.60$0.67Beat
Jul 24, 2025$0.62$0.67Beat
Apr 23, 2025$0.60$0.64Beat

Analyst view

Consensus price target
$104.63 ▲ +17.5%
Range $95.00 – $110.00
Rating: Buy
Buy 67% · Hold 33% · Sell 0%

Get free alerts on EW and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.